Journal of Schizophrenia Disorders And Therapy
Join a distinguished global community of psychiatrists, clinical psychologists, schizophrenia researchers, psychopharmacologists, neuroscientists, mental health specialists, psychiatric nurse practitioners, cognitive behavioral therapists, psychiatric social workers, and translational scientists dedicated to advancing understanding of schizophrenia spectrum disorders, psychotic disorders, first-episode psychosis, treatment-resistant schizophrenia, antipsychotic pharmacotherapy, cognitive rehabilitation, psychosocial interventions, and evidence-based therapeutic innovations through cutting-edge research, clinical trial findings, and collaborative scientific investigations worldwide.
Why Join Our Research Network?
The Journal of Schizophrenia Disorders And Therapy offers exclusive membership benefits to psychiatrists, clinical psychologists, schizophrenia researchers, psychopharmacologists, psychiatric nurses, cognitive behavioral therapists, psychiatric social workers, and mental health professionals advancing schizophrenia research, evidence-based treatment development, clinical treatment innovation, improved patient outcomes, and comprehensive recovery-oriented care worldwide.
Reduced Publication Fees
Members receive up to 45% discount on article processing charges for all accepted manuscripts, making schizophrenia research accessible to academic psychiatric departments, mental health hospitals, research universities, clinical practices, pharmaceutical companies, and independent investigators conducting psychosis research, antipsychotic studies, and cognitive rehabilitation trials worldwide.
Unlimited Submissions
Submit unlimited research manuscripts annually with comprehensive double-blind peer review from leading schizophrenia specialists, psychiatrists, clinical psychologists, and psychopharmacology experts ensuring rigorous scientific evaluation, constructive feedback, methodological guidance, and adherence to the highest publication standards in psychiatric research.
Global Visibility
Your schizophrenia research reaches psychiatry departments, mental health centers, academic hospitals, pharmaceutical companies, biotechnology organizations, patient advocacy groups, clinical research organizations, and research institutions worldwide through extensive global indexing networks, search engine optimization, and open access distribution platforms for maximum research visibility.
Professional Recognition
Receive official membership certificate and digital credentials recognizing your commitment to schizophrenia research for grant applications, academic promotions, tenure reviews, fellowship applications, research funding proposals, and professional portfolio documentation.
Priority Peer Review
Members receive expedited manuscript processing with priority scheduling from our distinguished editorial board of schizophrenia experts, psychiatrists, clinical psychologists, neuropsychopharmacologists, and cognitive rehabilitation specialists with extensive expertise in psychotic disorders.
Editorial Support
Access professional language editing, comprehensive manuscript formatting assistance, figure preparation, statistical consultation for clinical trials, graphical abstract design, and dedicated customer support from our editorial team throughout your membership period.
Select Your Membership Level
Flexible membership options designed for psychiatrists, schizophrenia researchers, clinical psychologists, psychiatric nurses, graduate students, postdoctoral fellows, academic institutions, pharmaceutical companies, and research organizations advancing schizophrenia understanding, psychopharmacological treatment development, cognitive rehabilitation programs, and patient care outcomes improvement worldwide.
Graduate students, doctoral candidates, postdoctoral researchers, and early-career psychiatric researchers
- 30% APC Discount
- Unlimited Submissions
- Peer Review Access
- 1 User Account
Psychiatrists, clinical psychologists, schizophrenia researchers and mental health specialists
- 45% APC Discount
- Unlimited Submissions
- Priority Peer Review
- 1 User Account
Universities, academic medical centers, psychiatric hospitals and research institutes
- 45% APC Discount
- Unlimited Submissions
- Priority Peer Review
- 1-21+ User Accounts
Pharmaceutical companies, biotechnology organizations and clinical research firms
- 45% APC Discount
- Special Issue Access
- Priority Peer Review
- 10-15 User Accounts
How to Become a Member
Begin your membership journey with these three straightforward steps and start publishing your schizophrenia research discoveries, psychopharmacology innovations, clinical trial findings, and therapeutic advances to our extensive global network of psychiatrists, clinical psychologists, psychiatric researchers, and mental health professionals.
Choose Your Tier
Select the membership level that aligns with your schizophrenia research needs, clinical specialty, career development stage, institutional budget, anticipated publication goals, research collaboration objectives, and collaborative research requirements.
Submit Application
Email [email protected] with your full name, academic credentials, institutional affiliation, psychiatric or psychology research focus, schizophrenia research publications list, and preferred membership tier selection.
Start Publishing
Receive your official membership certificate, digital credentials, professional recognition, and member portal access, then begin submitting manuscripts for expedited peer review, priority publication consideration, and accelerated editorial decisions.
Frequently Asked Questions
Find answers to common questions about exclusive membership benefits, manuscript publication process, peer review timelines, editorial guidelines, submission requirements, and support services for schizophrenia researchers.
What research areas are covered?
The Journal welcomes original research on schizophrenia pathophysiology, psychotic disorders, first-episode psychosis, treatment-resistant schizophrenia, antipsychotic pharmacotherapy, cognitive behavioral therapy for psychosis, psychosocial rehabilitation, neuroimaging biomarkers, functional MRI studies, genetic susceptibility, and early intervention strategies for at-risk populations.
Can I upgrade my membership tier?
Yes, members can upgrade at any time during their active subscription period. Contact our dedicated membership services team for seamless tier transitions with prorated fees, updated benefits package, enhanced publication support, and continuous editorial assistance.
What is the peer review timeline?
Our rigorous double-blind peer review typically completes within 4-6 weeks. Members receive priority processing and expedited editorial decisions from our expert review board of schizophrenia specialists, psychiatrists, clinical psychologists, and neuropsychopharmacologists.
Are clinical trial papers accepted?
Absolutely. We actively encourage submissions of Phase I-IV clinical trial results, real-world effectiveness studies, comparative treatment analyses, patient-reported outcomes, long-term safety monitoring data, and antipsychotic efficacy studies.
How does open access benefit researchers?
Open access ensures your schizophrenia research reaches psychiatry departments, mental health hospitals, academic institutions, pharmaceutical companies, patient advocacy organizations, and research institutions worldwide without subscription barriers, maximizing research impact, citation potential, and collaborative opportunities.
What support services are available?
Members receive professional language editing, manuscript formatting assistance, figure preparation, statistical consultation for clinical trials, graphical abstract design, supplementary materials formatting, and dedicated customer support throughout your entire membership period.
Membership Renewal Guidelines
Maintain uninterrupted access to all exclusive member benefits, significant APC discounts, priority peer review processing, expedited editorial decisions, professional language editing services, dedicated editorial support, and comprehensive manuscript formatting support throughout your entire membership period.
Advance Schizophrenia Research Today
Join the distinguished global community of psychiatrists, clinical psychologists, schizophrenia researchers, psychopharmacologists, mental health specialists, and cognitive rehabilitation experts advancing understanding of psychotic disorders, antipsychotic therapeutics, and evidence-based interventions worldwide. Start publishing your groundbreaking research with discounted APC rates, priority peer review, expedited editorial decisions, and worldwide visibility through our comprehensive open access publishing platform.